Investment Thesis
Entrada faces acute financial distress with revenue collapsed 87.9% YoY to $875K while burning $41.7M in annual operating cash. Current cash position of $76.4M provides approximately 18-20 months of runway at present burn rates, creating urgent need for product validation, revenue stabilization, or capital raise.
Strengths
- Solid balance sheet with $270.9M stockholders equity and low leverage
- Strong short-term liquidity position with 13.9x current ratio and $76.4M cash
- Minimal debt burden providing financial flexibility and no near-term refinancing risk
Risks
- Catastrophic 87.9% YoY revenue decline indicating major product loss, partnership termination, or operational failure
- Severe cash burn of $41.7M annually against near-zero revenue generation creates extended runway depletion risk
- Completely unprofitable operations with operating margin of -4834% and no visible path to profitability without major business inflection
- As biotech company, dependent entirely on R&D pipeline success and FDA approvals with no near-term revenue diversification
- Insider Form 4 activity (10 filings in 90 days) may signal management concerns or capital raise preparations
Key Metrics to Watch
- Quarterly revenue trends and stabilization versus continued decline
- Operating cash burn rate changes and R&D expense management
- Clinical trial progress, FDA decisions, and pipeline advancement milestones
- Cash depletion rate relative to 18-20 month runway and any capital raise announcements
- Gross margin and operating margin trajectory once revenue base stabilizes
Financial Metrics
Revenue
875.0K
Net Income
-39.7M
EPS (Diluted)
$-0.95
Free Cash Flow
-41.7M
Total Assets
335.5M
Cash
76.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-4,834.6%
Net Margin
-4,539.1%
ROE
-14.7%
ROA
-11.8%
FCF Margin
-4,770.2%
Balance Sheet & Liquidity
Current Ratio
13.90x
Quick Ratio
13.90x
Debt/Equity
0.00x
Debt/Assets
19.3%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T10:31:06.027810 |
Data as of: 2026-03-31 |
Powered by Claude AI